Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer

Lasorsa, Francesco; Meo, Nicola Antonio di; Rutigliano, Monica; Ferro, Matteo; Terracciano, Daniela; Tătaru, Octavian Sabin; Battaglia, Michele; Ditonno, Pasquale; Lucarelli, Giuseppe

doi:10.3390/ijms24020910

Cited by 22 publications

(13 citation statements)

References 135 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, the introduction of high-throughput technologies has provided significant insights into the understanding of normal and pathological processes, as well as the identification of potential targets for the development of drugs to treat diseases such as cancer [55][56][57][58][59][60][61]. In particular, the analysis of low-molecular-weight metabolites (the metabolome) allows for the global assessment of a cellular state in normal and pathological conditions.…”

Section: Discussionmentioning

confidence: 99%

Management of Pediatric Urolithiasis in an Italian Tertiary Referral Center: A Retrospective Analysis

Lasorsa,

Caliolo,

Silecchia

et al. 2023

Medicina

Self Cite

View full text Add to dashboard Cite

Background and Objectives: In recent years, the prevalence of pediatric urolithiasis has increased in North America and Western countries, though it is endemic in developing countries. The aim of this study is to describe the experience of a tertiary pediatric referral center in the surgical management of pediatric urolithiasis. Materials and Methods: We retrospectively reviewed the experience of patients ≤ 16 years old affected by urinary stones who underwent surgery. Results: From April 2021 to September 2023, 31 pediatric patients underwent surgical procedures for stone diseases at our department: 13 preschool-aged (1–5 years) and 18 school-aged (6–16 years) children. During this period, 12 URSs, 17 RIRSs, and 2 PCNLs were recorded. Five patients had residual fragments at first, so three of them underwent a second endourological lithotripsy (2 RIRSs and 1 URS). Complete clearance was finally achieved in 27 patients. The stone composition was evaluated in 25 cases. Conclusions: Numerous innovations in the surgical treatment of pediatric urolithiasis have resulted from the development of smaller devices and new technology. Our results show how, in experienced centers, retrograde and percutaneous lithotripsy are safe and effective procedures for use in pediatric populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Management of Pediatric Urolithiasis in an Italian Tertiary Referral Center: A Retrospective Analysis

Lasorsa,

Caliolo,

Silecchia

et al. 2023

Medicina

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fibroblasts are the major components of the stroma of PC (Pederzoli et al 2023 ). Fibroblasts are necessary for cancer progression, cancer metastasis, and being androgen-independent (Lasorsa et al 2023 ). A recent study was conducted on three prostate cancer cell lines (PC-3 and DU-145, and LNCaP) and healthy prostate cells as control (PNT-1) (Pietrovito et al 2020 ).…”

Section: Cannabis In Prostate Cancermentioning

confidence: 99%

Cannabis and cancer: unveiling the potential of a green ally in breast, colorectal, and prostate cancer

ALSalamat,

Abuarab,

Salamah

et al. 2024

J Cannabis Res

View full text Add to dashboard Cite

Cancer comes in second place on the list of causes of death worldwide. In 2018, the 5-year prevalence of breast cancer (BC), prostate cancer (PC), and colorectal cancer (CRC) were 30%, 12.3%, and 10.9%, respectively. Cannabinoids are chemicals derived from the Cannabis sativa plant; the most investigated cannabinoids are cannabinol, delta 9-tetrahydrocannabinol (Δ9-THC), and cannabidiol. In humans, the endogenous endocannabinoid system consists of endocannabinoids, cannabinoids receptors (CBs), and enzymes that degrade the endocannabinoids. In this review, we will review the most recent literature for evidence that discusses the role of cannabis in the treatment of the three types of neoplasms mentioned. Studies have proved that BC cells express CB receptors; many in-vivo studies showed that cannabinoids cause apoptosis and inhibit proliferation and migration. Also, researchers found that treating BC mice with THC and JWH-133 (CB2 receptor agonist) slowed the tumor growth. Regarding CRC, cannabidiol was found to decrease the viability of chemotherapy-resistant CRC cells and inhibit metastasis by antagonizing the G-protein-coupled receptor 55 (GPR55; a novel cannabinoid receptor) necessary for metastasis. Moreover, cannabidiol had anti-angiogenetic effects by reducing the expression of vascular endothelial growth factor (VEGF) in addition to anti-inflammatory effects. Finally, studies demonstrated that PC cells highly express CB1 and CB2 receptors and that cannabinoids are capable of inhibiting the release of exosomes and microvesicles related to cancer progression. Cannabinoids also have antiproliferative, anti-invasive, anti-fibroblastic, cell cycle arrest, and proapoptotic effects on PC cells.

show abstract

“…ARG1-expressing cells also include M2-TAMs and T regs [ 47 ]. Reduced levels of these amino acids impair T cell proliferation [ 48 , 49 ]. In addition, regulatory T cells (Treg) may dampen T cell responses at tumor sites and lymph nodes.…”

Section: Cancer Immune Surveillance and Escape Mechanismsmentioning

confidence: 99%

Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice

et al. 2023

Self Cite

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the seventh most common cancer in men and the ninth most common cancer in women worldwide. There is plenty of evidence about the role of the immune system in surveillance against tumors. Thanks to a better understanding of immunosurveillance mechanisms, immunotherapy has been introduced as a promising cancer treatment in recent years. Renal cell carcinoma (RCC) has long been thought chemoresistant but highly immunogenic. Considering that up to 30% of the patients present metastatic disease at diagnosis, and around 20–30% of patients undergoing surgery will suffer recurrence, we need to identify novel therapeutic targets. The introduction of immune checkpoint inhibitors (ICIs) in the clinical management of RCC has revolutionized the therapeutic approach against this tumor. Several clinical trials have shown that therapy with ICIs in combination or ICIs and the tyrosine kinase inhibitor has a very good response rate. In this review article we summarize the mechanisms of immunity modulation and immune checkpoints in RCC and discuss the potential therapeutic strategies in renal cancer treatment.

show abstract

Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer

Cited by 22 publications

References 135 publications

Management of Pediatric Urolithiasis in an Italian Tertiary Referral Center: A Retrospective Analysis

Management of Pediatric Urolithiasis in an Italian Tertiary Referral Center: A Retrospective Analysis

Cannabis and cancer: unveiling the potential of a green ally in breast, colorectal, and prostate cancer

Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice

Contact Info

Product

Resources

About